10-K · February 26, 2026
Revelation Biosciences is a clinical-stage company developing Gemini (PHAD®) as an immunomodulatory therapy focused on AKI and CKD. The 10-K reports an end‑of‑2025 regulatory milestone — the company “obtained agreement…
Earnings analysis · 10-Q
REVB earnings analysis
Filed May 7, 2026 · Our reading of the company's report
The latest report
Revelation Biosciences reported a net loss of $3.0 million for Q1 2026, compared to a net loss of $2.1 million for Q1 2025, indicating increased operational expenses. The Company's cash and cash equivalents stood at…
Read full summary
Revelation Biosciences reported a net loss of $3.0 million for Q1 2026, compared to a net loss of $2.1 million for Q1 2025, indicating increased operational expenses. The Company's cash and cash equivalents stood at $14.1 million as of March 31, 2026, but they expressed substantial doubt about their ability to continue as a going concern without additional funding.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-3.09
What stood out
-
Increased Net Loss YoY
Net loss increased to $3.0M in Q1 2026 from $2.1M in Q1 2025.
-
Cash and Cash Equivalents
Cash and cash equivalents totaled $14.1M as of March 31, 2026.
-
R&D Expense Growth
Research and development expenses rose from $858,830 in Q1 2025 to $1.4M in Q1 2026.
-
GEM-AKI Manufacturing Costs
GEM-AKI manufacturing expenses accounted for $314,304 of R&D costs in Q1 2026.
-
Professional Fees Increase
General and administrative expenses grew by $0.5M to $1.7M driven by professional fees and personnel costs.
-
Funds Raised via Warrants
Net proceeds of approximately $6.7M were raised from warrant exercises during Q1 2026.
What to watch
-
Doubt About Going Concern
Management indicates that current cash may not support operations beyond one year.
-
Recurring Operating Losses
The Company has incurred significant losses since inception, with a total accumulated deficit of $52.4M.
-
Potential Nasdaq Delisting
Risk of delisting if the Company fails to meet Nasdaq's capitalization and liquidity requirements.
Management's outlook
Outlook deferred to earnings press release / call.
Earlier filings 4
10-Q · November 6, 2025
Revelation Biosciences reported a three-month net loss of $1,907,176 for the period ended September 30, 2025 (improving $334,389 vs. $2,241,565 in the prior-year quarter) and a nine‑month net loss of $6,402,643…
10-Q · May 8, 2025
Revelation Biosciences reported a Q1 net loss of $2,051,085 (Q1 2024: $2,681,433), improving by $630,348 year-over-year, and reported EPS of -$2.11. R&D and G&A rose modestly to $858,830 and $1,236,157, respectively.…
10-Q · November 8, 2024
Revelation Biosciences reported a Q3 2024 net loss of $2,241,565 (EPS -$0.84), an improvement versus Q3 2023 net loss of $2,628,376 (EPS -$9.94). Operating expenses declined to $1,796,686 from $2,777,897, driven by…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.